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Abstract
The Asia-Pacific region has made significant progressBackground: 
against malaria, reducing cases and deaths by over 50% between 2010
and 2015. These gains have been facilitated in part, by strong political and
financial commitment of governments and donors. However, funding gaps
and persistent health system challenges threaten further progress.
Achieving the regional goal of malaria elimination by 2030 will require an
intensification of efforts and a plan for sustainable financing. This article
presents an investment case for malaria elimination to facilitate these
efforts.
A transmission model was developed to project rates of declineMethods: 
of   and   malaria and the outputPlasmodium falciparum Plasmodium vivax
was used to determine the cost of the interventions that would be needed
for elimination by 2030. In total, 80 scenarios were modelled under various
assumptions of resistance and intervention coverage. The mortality and
morbidity averted were estimated and health benefits were monetized by
calculating the averted cost to the health system, individual households,
and society. The full-income approach was used to estimate the economic
impact of lost productivity due to premature death and illness, and a return
on investment was computed.
: The study estimated that malaria elimination in the region by 2030Results
could be achieved at a cost of USD 29.02 billion (range: USD 23.65-36.23
billion) between 2017 and 2030. Elimination would save over 400,000 lives
and avert 123 million malaria cases, translating to almost USD 90 billion in
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and avert 123 million malaria cases, translating to almost USD 90 billion in
economic benefits. Discontinuing vector control interventions and reducing
treatment coverage rates to 50% will result in an additional 845 million
cases, 3.5 million deaths, and excess costs of USD 7 billion. Malaria
elimination provides a 6:1 return on investment.
 This investment case provides compelling evidence for theConclusion:
benefits of continued prioritization of funding for malaria and can be used to
develop an advocacy strategy.
Keywords
malaria, elimination, financing, costs, government, donor, resource
mobilization
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Introduction
The Asia-Pacific region has achieved significant gains against 
malaria over the last decade. Malaria cases and deaths have 
declined by more than 50% between 2010 and 2015 in the 
region’s 21 malaria-endemic countries1. Sri Lanka was declared 
malaria-free in 2016, becoming only the second country in 
Southeast Asia, after the Maldives, to successfully eliminate 
malaria. Apart from India, Indonesia, Myanmar, and Thailand, 
malaria-endemic countries have reported reductions in malaria 
incidence of more than 75% since 2000. In Bhutan, China, 
and Timor-Leste, cases have declined by almost 100%, with less 
than 200 cases being reported in 20161.
Progress in driving down malaria may be attributed to a number 
of factors. Strong political and financial support from gov-
ernments and donors like the Global Fund to Fight AIDS, 
Tuberculosis and Malaria (the Global Fund) has enabled the 
scale-up of effective interventions to prevent, diagnose, and treat 
malaria. Financing for malaria in the Asia-Pacific region 
increased from less than USD 100 million in 2000 to about USD 
415 million in 2016. Between 2006–2010, the Asia-Pacific 
region attracted between 12% and 21% of global malaria funding 
from the Global Fund to Fight AIDS, Tuberculosis and Malaria 
(hereafter Global Fund)2. However, there has been a steady 
decline in external financing for malaria in several coun-
tries, particularly those that are middle-income and experience 
relatively lower malaria transmission3. Although domestic 
financing for malaria has increased in many countries in the last 
decade, the need for malaria control and elimination far exceeds 
the available resources, particularly in the context of elimination 
where malaria is no longer perceived as a priority disease.
Despite the progress and opportunities for elimination, malaria 
remains a major cause of death and illness in the region, with 
an estimated 228 million cases being reported in 20184. The 
recent gains made are fragile and investments could be lost if 
malaria resurges. The case for malaria elimination has never 
been stronger, particularly with the growing threat of antimalarial 
drug resistance arising from the Greater Mekong Subregion 
(GMS) and the risk of it spreading to other regions. However, 
in order to achieve a malaria-free Asia-Pacific—a goal 
endorsed by leaders at the highest levels though the Asia-Pacific 
Leaders Malaria Alliance (APLMA)2—financial resources will 
need to be sustained5. Reduced funding or political commitment 
has historically been linked to 75 resurgences of malaria in 
61 countries since the 1930s6.
Countries and partners need better estimates of the resources 
required to eliminate malaria in the long term, as well as evi-
dence on the financial and economic benefits of investing in its 
elimination in order to advocate for more resources. The objectives 
of this study were to estimate the cost to achieve malaria elimi-
nation in the Asia-Pacific region by 2030; generate an investment 
case for malaria by estimating the economic benefits of malaria 
elimination and prevention of reintroduction (POR); and iden-
tify the funding gaps and explore the potential opportunities for 
generating additional financial resources for achieving malaria 
elimination goals.
Financing for malaria in the Asia-Pacific region
The main sources of financing for malaria in Asia-Pacific are 
domestic government resources and external financing from 
donors. Although domestic financing for malaria has increased 
by over 40% in Asia-Pacific between 2015–2017 compared to 
2012–20147, most national malaria control programs (NMCPs) 
in the region continue to be highly reliant on external financing, 
particularly from the Global Fund. As Figure 1 illustrates, 
almost 50% of the total funding for malaria in Asia-Pacific in 
1The Asia-Pacific region in this report encompasses the 21 malaria-
endemic countries as defined by APLMA. Sri Lanka has since been declared 
as malaria free but still implements prevention of reintroduction activities. 
Countries include: Afghanistan, Bangladesh, Bhutan, Cambodia, Democratic 
People’s Republic of Korea (DPRK), India, Indonesia, Lao People’s 
Democratic Republic (Lao PDR), Malaysia, Myanmar, Nepal, Pakistan, Papua 
New Guinea (PNG), People’s republic of China, Philippines, Republic of 
Korea (ROK), Solomon Islands, Sri Lanka, Thailand, Timor Leste, Vanuatu 
and Vietnam.
2At the 2013 East Asia Summit (EAS), the Asia-Pacific Leaders Malaria 
Alliance (APLMA) was established to accelerate progress towards a reduction in 
malaria cases and deaths. In 2014 at the ninth EAS, the APLMA Co- Chairs 
(the Prime Ministers of Viet Nam and Australia) tabled a recommendation 
for the Asia-Pacific region to become free of malaria by 2030. EAS Heads 
of Government agreed to the goal, and tasked APLMA Co- Chairs to present 
a plan to reach malaria elimination through a “Leaders’ Malaria Elimination 
Roadmap”8. The APLMA roadmap was presented to Heads of Government 
during the 10th EAS Meeting in 2015.
            Amendments from Version 1
This version includes revisions according to comments from the 
two reviewers. Most of these revisions are clarity on text further 
depth as requested.
Any further responses from the reviewers can be found at the 
end of the articles
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2016 was from the Global Fund. This dependence on external 
financing is projected to continue8.
Methods
This investment case was one part of a larger study in which 
a transmission model9,10 and an interactive application was 
developed11. All three papers are included in this series. The 
methodology specific to the investment case is included in the 
sections below entitled “cost projections” onwards.
The overall study design incorporated a variety of quantita-
tive methods: numerical and regression techniques to develop 
a transmission model to predict the epidemiological impact of 
various interventions used for malaria control and elimination; 
and economic analysis to estimate the cost and economic impact 
of the interventions nationally and regionally. The population 
studied was the population at risk of malaria estimated by the 
WHO. This was computed as the proportion of the population at 
high and low risk of malaria (provided by the National Malaria 
Control Programs) applied to the United Nations population 
estimates to compute the number of people at risk of malaria. 
A combination of empirical, published data as well as expert 
opinion were used to develop the investment case.
Model framework
We used outputs from a mathematical transmission model to 
estimate the costs and benefits of malaria elimination. The 
model is a dynamic compartmental model that incorporates the 
transmission dynamics of both P. falciparum and P. vivax 
malaria and interactions between the two species of malaria9.
A spatially dependent version of this multi-species model was 
applied at a national level to the 22 countries in the Asia-Pacific. 
This facilitated the estimation of the relative contribution of 
interventions in a spatially heterogeneous transmission set-
ting. The region was partitioned into a number of interconnected 
patches with each patch representing a country having its own 
transmission intensity. Spatial dependence between the patches 
was incorporated such that the risk of infection of an individual 
in one patch from an individual in another patch was negatively 
correlated with the distance between the centroids of the 
patches9,10.
The model was validated separately against the estimated 
burden of disease for P. falciparum and P. vivax (presented 
elsewhere12) and accumulated case mortality. Several indica-
tors (such as the estimated incidence of all malaria species and 
reported fatalities) were modelled for each country between 2016 
and 2030, under scenario-specific assumptions. A total of 80 sce-
narios were simulated, based on 10 different sets of packages of 
interventions. These ranged from discontinuing most malaria 
activities to a very substantial scale-up of interventions, which 
could be supplemented by mass drug administration (MDA) or 
an increase in the coverage of long-lasting insecticide-treated nets 
(LLINs), at either a stable or increasing trajectory of drug resist-
ance. While the reported coverage of interventions (particularly 
LLINs and indoor residual spraying (IRS)) were included in the 
model to inform changes in incidence, there was little available 
data on coverage of other interventions between 2000 and 2015, 
such as the introduction of community health workers). These 
coverage statistics were therefore imputed based on observed 
changes in reported incidence. The mortality predicted by the 
model was validated against reported deaths. A full description 
of the model is available elsewhere9,10.
The model estimated the impact of several intervention scenarios 
on the transmission of P. falciparum and P. vivax malaria from 
2016 to 2030 in each of the 22 countries. Data used to 
Figure 1. Financing for malaria in the Asia-Pacific region by source: unpublished data from the global fund.
Page 4 of 25
Wellcome Open Research 2020, 4:60 Last updated: 22 JAN 2020
calibrate and validate the model were sourced from World Malaria 
Reports (2001–2016)13–20 and peer reviewed literature21–23. While 
reported coverage of interventions (particularly LLINs and IRS) 
were included in the model to inform changes in incidence, 
there was little available data on health system advances 
between 2000 and 2015 (such as the introduction of community 
health workers); thus, these were imputed based on observed 
changes in reported incidence. The mortality predicted by 
the model was validated against reported deaths.
Elimination scenarios
A total of 80 scenarios were generated. Four counterfactual 
scenarios (No. 1–4 in Table 1) including one “business as usual” 
scenario was modelled in which coverage remained the same 
as for 2016 (the last data point for which covariate rates were 
available for all 22 countries), and three reverse scenarios that 
simulated the potential impact of scaling down the malaria 
program. The six elimination scenarios (No. 5–10 in Table 1 
were modelled sequentially to increase in complexity and in the 
number of interventions included.
For each country, the minimum package of interventions that 
would achieve malaria elimination was determined, defined 
here as one year with less than one reported clinical case. This was 
taken to be the minimum elimination scenario for that particular 
country. Since the model did not distinguish between indig-
enous and imported cases, we assumed that certain thresholds 
of cases are imported, which we subtracted from the model 
outputs. Using Sri Lanka’s example of achieving elimination 
status in 2016, but reaching zero indigenous cases in October 
2012, the elimination threshold was defined as the inci-
dence per 1000 population at risk that Sri Lanka reported 
to WHO in 2013. This was taken to be a proxy for the level of 
imported cases one would expect to see in a country that has 
reached zero indigenous cases for the first time. This threshold 
was applied to the population at risk for all 22 countries.
In addition, we simulated the effect of improved targeting 
of malaria interventions on both costs and epidemiological 
outputs. We did this by reducing intervention coverage by 
30% among the population at risk (PAR) for all scenarios, with 
and without the resistance and MDA assumptions. The out-
puts of averted mortality and morbidity under the elimina-
tion scenarios were expressed as reported cases and deaths 
(projected from reported cases) and estimated cases and deaths 
projected from a range of estimates. Averted cases and deaths 
were then used to estimate the cost, benefits, and returns on 
investment (ROIs).
Table 1. Modelled scenarios used in the transmission model.
Scenario Description
1 Business as usual •   Continue all interventions at 2015 levels from 2016 through 2030
2 Reverse scenario 1 •   Business as usual 
•   IRS activities ceased
3 Reverse scenario 2 •   Reverse scenario 1 
•   Distribution of new LLINs ceased
4 Reverse scenario 3 •   Reverse scenario 2 
•   Treatment rates reduced by 50%
5 Universal coverage •   Business as usual 
•    Coverage of population at risk with test and treat increased from 2017 onwards in a linear fashion 
over eight years to 80% by 2025
•   Quinine is switched to injectable artesunate for management of severe disease in 2017
6 IRS •   Universal coverage 
•   IRS coverage in 2017 doubled in a linear fashion over eight years
7 Effective usage •   Universal coverage 
•   Effectiveness of LLINs increased 
•   Surveillance increased
8 New P. vivax treatment •   Effective usage 
•   Replace primaquine with a new P. vivax treatment
9 New LLINs •   New P. vivax treatment 
•   Life of LLINs doubled
10 New P. falciparum 
treatment
•   New LLINs 
•    First-line Artemisin based Combiantion Therapy (ACT) replaced with new candidate for 
P. falciparum treatment
Assumption Description
A Artemisinin and ACT 
resistance
5% probability of treatment failure from ACTs across all countries is constant until 2018 and then 
increased to 30% through 2025
B MDA Five annual rounds of MDA at 50% coverage from 2018 starting four months before the peak of the 
transmission season targeted at both species
C LLINs Scaling up LLINs to 80% effective coverage deployed in a 3-year cycle (50%, 25% and 25%)
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Additional assumptions
We applied additional assumptions to simulate various possible 
outcomes across all 10 scenarios: (i) The first was around the 
occurrence of artemisinin and ACT partner drug resistance; 
across all scenarios, a baseline treatment failure rate of 5% 
was applied across all countries from 2016–2030. Under the 
resistance assumption, the probability of treatment failure 
was kept constant at 5% through 2018 and increased to 30% 
between 2018 and 2025. (ii) The second assumption concerned 
the use of MDA. MDA was simulated as five annual rounds 
of dihydroartemisinin-piperaquine at 50% coverage of the 
population at risk from 2018 onwards, starting four months before 
the peak of the malaria transmission season. (iii) In a third set 
of simulations, LLIN scale-up was added to all the elimination 
scenarios in accordance with WHO guidelines for vector 
control, if malaria elimination was not predicted by 2030. LLIN 
scale-up was defined as LLIN coverage of up to 80% coverage 
achieved through three-year distribution cycles from 2017 to 
2026. These additional rates of decline were projected separately.
These additional scenarios produced a total of 80 scenarios: with 
and without resistance; with and without MDA; and with and 
without LLIN scale up to 80%.
PAR
Population at risk is traditionally difficult to estimate and depends 
on the national malaria program’s assessment of active, residual 
and non-active foci, among other things. The study relied on the 
PAR estimates reported in the World Malaria Report, as a single 
source for all 22 countries, though the definitions are not stand-
ardized. For all the scenarios, a declining PAR was assumed 
in the model. PAR values used to estimate costs in the model 
were adjusted to reflect the decreases in incidence predicted from 
the implementation of elimination-focused interventions. His-
torical incidence and PAR data were analysed statistically to infer 
a predicted change in PAR for a given change in incidence. 
This relationship was applied to the 2015 PAR data and updated 
every year until 2030 as interventions were applied in the mod-
elled scenarios. This method has limitations, including a non- 
standardized definition of PAR between countries.
Cost projections
We used the outputs of the transmission model to estimate the 
total costs associated with implementing each of the scenarios 
above. Program costs included the costs of testing and treating 
uncomplicated or outpatient (OP) and severe or inpatient (IP) 
malaria cases; vector control (i.e., LLIN distribution and IRS); 
supply chains; surveillance through community health work-
ers; information, education, communication; training; MDA; new 
treatments (e.g., tafenoquine for P. vivax); and rollout of new 
LLINs. Unit costs for each activity were obtained using a com-
bination of empirical data collected in various Asia-Pacific 
countries by the authors, literature reviews, and proxies when 
the previous options were unavailable (Table E1, available as 
extended data24). From the range of costs generated, we determined 
the minimum, maximum, median, mean, and other percentiles of 
the economic benefits.
In addition, we simulated the effect of improved targeting of 
malaria interventions on both costs and epidemiological outputs 
on cost. We did this by assuming a focal deployment of inter-
ventions where the target population comprises the high risk and 
only 70% of the low risk population.
The total cost of the elimination scenarios was used to build this 
investment case. We calculated the costs to reach elimination 
separately for each country and then summed them to obtain 
the total cost for elimination in the Asia-Pacific region. 
To calculate the incremental or additional costs of malaria 
elimination (which were used to calculate ROIs), we sub-
tracted the estimated costs of the business as usual and reverse 
scenarios from the elimination scenario. All monetary figures 
are expressed in 2015 constant USD.
Economic benefits estimation
Using outputs from the model, we estimated the mortality and 
morbidity averted from malaria elimination by subtracting the 
estimated cases and deaths of the elimination scenario from the 
corresponding outputs of the “business as usual” and “reverse” 
scenarios. We then monetized these health benefits by looking at 
the averted cost to the health system, averted cost to individual 
households, and averted cost to society:
• Cost averted to the health system includes costs associ-
ated with diagnosis and treatment costs of IPs and OPs;
• Cost averted to the individual households is out-of-pocket 
(OOP) expenditures for seeking care; and
• Cost averted to the society due to patients’ lost productiv-
ity due to premature death and morbidity and caregivers’ 
reduced economic output.
The same cost inputs used in the cost estimation were used 
for calculating the economic benefits. Unit costs for case 
management included costs for OP visits, diagnostic tests, and 
drug treatments for OP malaria cases, as well as hospital hotel 
costs and drug treatments for IP malaria cases. OOP expenditures 
were estimated by applying country-specific OOP expenditure per 
capita separately for OP and IP cases. We calculated produc-
tivity losses among patients and caretakers by multiplying an 
estimate of daily productivity by the number of days lost due 
to illness or care seeking.
We used the full-income approach to estimate the economic 
impact of lost productivity due to premature death from malaria. 
We multiplied the number of averted deaths for each country 
by the country-specific values of additional life years (VLYs) and 
life expectancies at age 40 among males and females, which was 
the assumed average age of death due to malaria25. One VLY was 
estimated to be 2.2 times the gross domestic product (GDP) 
per capita for each of the countries in South East Asia and the 
Pacific and 2.8 times the GDP per capita for each of the coun-
tries in South Asia, as suggested by the Lancet Commission on 
Investing in Health26.
Page 6 of 25
Wellcome Open Research 2020, 4:60 Last updated: 22 JAN 2020
All costs and economic benefits were discounted at 3%.
Return on investment
The ROI was calculated by subtracting the incremental cost of 
elimination from the economic benefits and dividing the result-
ing figure by the incremental cost of elimination. The ROI is 
interpreted as the economic return from every additional dollar 
spent on malaria elimination.
We performed the ROI analysis for 2016–2030 by comparing 
the elimination scenario with the business as usual and reverse 
scenarios under the stable and increasing resistance assumptions.
Uncertainty analysis
We performed stochastic sensitivity analysis on the epidemio-
logical and cost outputs of the malaria transmission model. The 
uncertainty interval of the epidemiological outputs was largely 
due to estimates of reporting coverage detailed in Maude et al. 
(2019)12
The minimum, median, and maximum malaria cases and deaths 
predicted by the model for each scenario were used to calculate 
the minimum, median, and maximum economic benefits. For the 
costs, we assigned an uncertainty interval of ±25% on the value 
of the input costs used. A total of 300 random samples were 
drawn, which generated a range of costs. From the range of costs 
generated, we determined the minimum, maximum, median, 
mean, and other percentiles of the economic benefits.
Gap analysis and opportunities for resource mobilization
Using available malaria financing data in the region (donor and 
domestic), between 2017 and 2020, we estimated the poten-
tial gap in financing assuming the total funding envelope 
would remain as projected. We also assessed potential oppor-
tunities for resource mobilization to fill financing gaps by 
mapping private sector investors and analysing the domestic 
funding landscape.
Results
Projected declines in transmission
The transmission model predicted that malaria elimination 
can be achieved by all the countries in the Asia-Pacific region by 
2030 by implementing a variety of scenarios. Table 2 illustrates 
the predicted output of the transmission model under an 
Table 2. Scenarios and predicted elimination dates.
Country Minimum elimination 
scenario and interventions
MDA LLIN Elimination date 
(predicted range)
National 
elimination goal
Afghanistan Effective usage Yes Yes 2025 (2025,2027) None
Bangladesh Effective usage No No 2025 (2024,2029) 2035
Bhutan Effective usage No No 2024 (2023, 2025) 2018
Cambodia New LLINs Yes No 2023 (2022, 2030) 2025
China Business as usual (already 
eliminated by 2017)
No No 2017 2020
DPRK New P. vivax drug No Yes 2028 (2027, 2030) 2025
India New LLINs No Yes 2028 (2026, 2030) 2030
Indonesia Effective usage Yes No 2025 (2022,2028) None
Lao PDR New P. falciparum drug Yes Yes 2025 (2022,>2030)
Malaysia IRS No No 
No
2023 (2019, 2029) 2020
Myanmar New P. falciparum drug Yes Yes 2025 (2024,>2030) None
Nepal Effective usage No No 2022 (2017, 2026) 2026
Pakistan Effective usage Yes Yes 2022 (2021, 2030) None
PNG Effective usage Yes No 2025 (2025,2028)
Philippines Effective usage No No 2021 (2017,2023) 2030
ROK Business as usual No No 2017 (2017,2019) 2017
Solomon Islands New LLINs Yes No 2028(2026, 2029)
Sri Lanka Business as usual (already 
eliminated by 2017)
No No Already eliminated 
in 2013
2012
Thailand New P. vivax drug No No 2026 (2025, 2029) 2024
Timor-Leste Universal coverage No No 2019 (2017,2024)
Vanuatu Effective usage Yes No 2021 (2021, 2024) 2025
Viet Nam Effective usage No No 2024 (2022, 2027) 2030
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Figure 2. Median predicted reported cases and deaths in the Asia-Pacific region, 2017–2030 under the business as usual scenario 
(BAU) and elimination scenario. These are predictions projected from the reported cases in 2015.
assumption of increasing artemisinin resistance and identifies 
the minimum elimination scenario defined as the scenario under 
which the country can achieve elimination on or before 2030 
with the least amount of effort.
The model predicted that it is possible for all 22 countries to 
achieve elimination of P. falciparum and P. vivax by 2030. 
China, ROK, and Sri Lanka3 are the only countries predicted to 
achieve elimination without scaling up current interventions. 
Elimination was predicted to be possible in Cambodia, DPRK, 
India, Lao PDR, Myanmar, Solomon Islands, and Thailand by 
2030 using new tools and technological innovation. Elimination 
was predicted to be possible by 2030 through the addition of 
MDA in Afghanistan, Cambodia, Indonesia, Lao, Myanmar, 
Pakistan, PNG, Solomon Islands, and Vanuatu. In all other 
countries, elimination is possible with the scale up of existing 
interventions.
Figure 2 illustrates the median reported cases and deaths between 
2016–30 under the “business as usual” scenario and minimum 
elimination scenarios for the region. These are predictions 
projected from the reported cases in 2015.
Figure 3 Illustrates the median estimated cases and deaths 
between 2016 and 2030 under the “business as usual” scenario 
and minimum elimination scenarios for the region. These are 
predictions projected from the estimated cases in 2015.
In the business as usual scenario for all countries in the region, 
clinical cases rose from an estimated 7 million in 2016 to 
15 million in 2030. Implementing the elimination scenario in 
each country will avert a total of over 123 million clinical cases 
and approximately 3.5 million deaths in the region over 14 years. 
In a “reverse” or worst case scenario, where interventions are 
halted and reduced (reverse scenario), cases increase to about 
180 million by 2030. There would be about 1 billion additional 
cases and 3.5 million additional deaths, costing an excess of 
USD 7 billion between 2016–2030.
Cost of malaria elimination through 2030
The cost of malaria elimination is shown in Figure 4 and Table 3 
The total cost to achieve malaria elimination in the Asia-Pacific 
between 2017 and 2030 was estimated to be USD 29.024 billion 
(range: USD 23.65–36.23 billion). The median cost in 
2017 for the elimination scenarios was USD 1.51 billion 
(range: USD 1.41–1.64 billion). Costs peak in 2020 at USD 
4.29 billion (range: USD 3.71–4.94 billion), then decrease to less 
than USD 1 billion in 2027 (range: USD 0.68–1.42 billion) and 
less than USD 450 million (range: USD 0.29–0.65 billion) in 
3Sri Lanka saw its last indigenous case in 2012 and obtained WHO certification 
in 2016.
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Figure 3. Median predicted estimated cases and deaths in the Asia-Pacific region, 2017–2030 under the “business as usual” scenario. 
minimum elimination and reverse scenarios.
Figure 4. Modeled costs of the elimination scenario, 2017–2030. Median and median +/- 25% costs of the modelled minimum elimination 
scenarios as well as an estimate of the median cost under a scenario of reduced PAR between 2017–2030.
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Table 3. Summary of costs and benefits, 2017–2030.
Scenarios compared Total cost (USD) Estimated clinical 
cases averted
Deaths averted Economic benefits 
(USD)
Incremental 
cost (USD)
ROI
Business as usual 
vs. elimination (with 
resistance assumption)
29.024 billion 
(range: 23.64–36.23)
123.14 million 
(estimated)4 
 
 
16.54 million 
(reported)5 
386,167 
(estimated) 
 
 
193,084 
(reported)
87.73 billion 
(range: 26.3–347.14)
14.05 billion 6:1
Business as usual vs. 
elimination (baseline)
28.953 billion 
(range: 23.38–35.72)
92.23 million 
(estimated clinical) 
 
 
11.68 million 
(reported) 
264,322 
(estimated clinical) 
 
 
132,161 
(reported)
72.90 billion 13.79 billion 5:1
Reverse vs. elimination 
(with resistance 
assumption)
NA 845.73 million 3.487 million N/A 6.693 billion N/A
4Projected from estimated cases
5Projected from reported cases
2030 when elimination is expected to be achieved in all 22 
countries. Lower costs incurred are expected to continue after 
the elimination date as POR of malaria interventions continue. 
The reverse scenario would cost an excess of USD 7 billion 
between 2017 and 2030. If interventions were only applied to 
70% of the PAR in the low-transmission areas (a crude proxy for 
the effect of improved targeting of interventions), the total cost 
would be about USD 22.49 billion.
Figure 5 illustrates how the relative costs are skewed by sub 
region with over 80% of the costs predicted to be incurred in 
South Asia, most notably, India.
Economic benefits estimation
Compared to a business as usual scenario, interrupting local 
transmission can save over 400,000 lives and avert 123 million 
malaria cases, translating to almost USD 90 billion (range: 
USD 26.3–347.14 billion) in economic benefits. The economic 
benefits included costs averted for diagnosis and treatment costs 
as inpatients and outpatients, costs averted to individual and 
households and the monetized value of lost productivity due 
to premature death and morbidity and caretaker’s reduced 
economic output as a result of taking care of patients.
Discontinuing vector control interventions and reducing 
treatment coverage rates to 50% will reverse the gains made, 
resulting in an additional 845 million cases, 3.5 million deaths, 
and excess costs of USD 7 billion.
Return on investment
The cost of malaria elimination was weighed against the 
epidemiological and economic costs of inaction. When the net 
benefits of elimination compared to the cases and costs averted 
in the business as usual scenario of the transmission model for 
the period of 2017 to 2030, the median ROI for each additional 
dollar invested in malaria elimination was calculated to be over 
6:1. This increases to 7:1 if interventions are better targeted in 
low-risk areas.
Financial gap
A median resource envelope of about USD 3 billion is needed 
annually to achieve elimination between 2018–2020. Total 
financing for the region is projected to be USD 0.5 billion 
annually for 2018–2020. Therefore, the anticipated gap is 
likely to be over 80% of the resources required for 
elimination between 2018–2020.
Sensitivity analysis
Figure 6 illustrates the sensitivity of the total cost to the indi-
vidual cost inputs. At the peak in 2020, costs vary from USD 
2.5 billion to USD 7 billion.
Figure 7 illustrates that using minimum values of the benefits 
will still produce a positive ROI.
Discussion
This analysis compared the monetized value of expected 
benefits from malaria elimination to the investment costs over 
a 14-year investment period (2017–2030) in the 22 countries of 
the Asia-Pacific, demonstrating a robust median return of about 
six times the incremental investment.
The study found that by employing a variety of existing and 
new interventions, all countries in the Asia-Pacific could elimi-
nate malaria by 2028—two years before the 2030 APLMA 
regional goal. The health, social, and economic returns are 
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Figure 6. Sensitivity of the total cost to the individual cost inputs (2016–2030).
Figure 5. Modeled costs by country and region of the elimination scenario from 2016 to 2030.
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Figure 7. Sensitivity of the ROI to varied costs and benefits.
potentially formidable. Malaria elimination will save over 
400,000 lives and avert over 123 million cases, translating to 
economic benefits of almost USD 90 billion.
Our models estimate that the total cost of achieving elimina-
tion and POR is about USD 29.02 billion (range: USD 23.64- 
36.23 billion) over 14 years or USD 12 billion between 2017–2020. 
Costs are highest in the first 4 years of efforts peaking at over 
USD 4 billion in 2020. These costs subsequently decline as more 
and more countries begin eliminating the disease and moving 
into POR interventions. By 2030, the cost of POR was esti-
mated to be less than USD 500 million. Successfully achieving 
elimination, will however require sustained financial resources.
Using co-financing data from Global Fund concept notes, total 
financing for malaria was projected at USD 1.4 billion between 
2018–2020, leaving an annual gap of about USD 2.5 billion or 
80% of the estimated cost of elimination.
Numerous countries in the region continue to rely on Global 
Fund resources to provide up to 50% of their total financing for 
malaria elimination. However, the allocation methodology 
adopted by the Global Fund in 2012, utilizes a combination of 
disease burden and gross national income (GNI) per capita to 
determine the financing that countries will receive24. By defi-
nition, malaria-eliminating countries have lower disease bur-
dens, have higher incomes and are therefore a lessor priority for 
donors. Country-specific funding from the Global Fund to the 
sub-set of countries attempting to eliminate malaria has declined 
by over 30%2. Further declines in allocations have been noted 
under a subsequently revised model adopted in November 201627. 
Given the downward trend in malaria burden and the region’s 
rising economic status, this level of support is likely to be even 
more diminished in subsequent years.
Many malaria-eliminating countries are middle-income coun-
tries (MICs) as defined by the World Bank28. The International 
Monetary Fund (IMF) projects average annual GDP growth rates 
of 3–10%, which means that economies in Asia will double or 
triple in size in the next decade. By 2020, four countries in Asia 
that are currently lower-middle-income countries (LMICs); 
Bhutan, Indonesia, the Philippines, Sri Lanka, will surpass the 
World Bank threshold for MICs of USD 4,125 GDP per capita24. 
This means that while there is increased potential for domestic 
financing, more countries will also start to graduate out of aid 
eligibility. Of the 22 countries in the Asia-Pacific region, three 
are currently LICs, 15 are LMICs, and three are UMICs and one 
is an UIC. There are 18 currently eligible for Global Fund 
financing29, out of which an additional two countries will be 
receiving the final transitional grants in the next two years (the 
Philippines and Sri Lanka). Political and policy changes in 
other donor constituencies also pose similar risks.
These changing polices have major implications for the financ-
ing and delivery of health services, for malaria elimination. 
Malaria financing will therefore need to depend on larger con-
tributions from government budgets. Indeed, the expectation 
of the economic and health financing transition suggests that as 
countries develop they will spend more on health than they did 
before. Although domestic financing for malaria has increased by 
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over 40% in the Asia-Pacific between 2015 and 2017 compared 
to 2012–20148, the resources required far exceed the amounts 
available.
The potential consequences of funding gaps at this critical 
juncture can be serious. This analysis estimates that scaling 
back interventions in the Asia-Pacific could lead to an additional 
3.5 million deaths, almost 1 billion cases, and economic costs 
of almost USD 7 billion. Emerging artemisinin resistance 
further threatens the gains made against malaria and regional 
health security with estimates of 9,560 excess deaths and USD 
51 million in productivity losses annually30.
To ensure uninterrupted availability of key malaria interven-
tions, mechanisms to augment and prioritize domestic funding 
and improve efficiencies in the existing malaria envelope will 
need to be explored. The Addis Ababa Action Agenda calls on 
a number of resource mobilization efforts encompassing aid, 
domestic public resources, and support from the private sector31.
Many national governments are considering raising health budg-
ets by improving the capacity to raise tax revenue including the 
implementation of Pigovian or sin taxes. In the Philippines, 
increased taxes on tobacco and alcohol generated USD 2.3 billion 
within just 2 years, increasing the Department of Health budget 
by 63% in 201532. This revenue has freed up resources, which 
would have otherwise been used for social protection of the poor. 
Indonesia and Vietnam have similarly implemented such 
revenue generating structures.
The diversification of Asia-Pacific countries’ economies presents 
a unique opportunity to engage the private sector in malaria 
elimination33. Private Asian companies such as AirAsia, Samsung, 
the Tata group, and Alibaba have become internationally rec-
ognizable brands. Government incentives for the private sector 
engagement could include tax relief or tax credit schemes and 
policies that promote expansion or diversification of programs. 
For example, the Cambodian Ministry of Health has developed 
a policy framework for public-private partnerships in the health 
sector. Similarly, an airline levy such as the UNITAID model 
could raise more than USD 300 million per year34.
The private sector may also be leveraged to provide in-kind con-
tributions and applying their business expertise to the malaria 
elimination challenge. For example, in 2010, the Coca-Cola 
Company launched a pilot project alongside the Global Fund 
and the Bill & Melinda Gates Foundation to transfer core exper-
tise to Tanzania’s Medical Stores Department, which distributes 
medical supplies across the country. This initiative “Project 
Last Mile” partnership was expanded in 2014 to include new 
partners with a goal to support 10 countries by 202035.
Innovative financing options can also fill the gap between needs 
and resources until government budgets catch up with the 
financing transition. These may include health bonds, debt swaps, 
and blended financing mechanisms. Social impact bonds and 
development impact bonds are other types of instruments that 
have been implemented in selected settings36. One example is the 
Mozambique Malaria Performance Bond, which is being used 
to raise funding from investors interested in both financial and 
social returns37,38. Such innovative instruments have been used to 
raise financing for health and other sectors, such as education and 
environment.
Multilateral Development Banks (MDBs) and partners can pro-
vide new financing opportunities to governments and the private 
sector, including cross-sectoral financing for health programs, 
incentivizing companies to invest in health interventions39. Coun-
tries can seek out additional grants and soft-loans from MDBs 
to help frontload the costs of elimination. Several MDBs are 
currently engaged in innovative models including ADB, the 
Inter-American Development Bank, the Islamic Develop-
ment Bank, and others in collaboration with the Bill & Melinda 
Gates Foundation, the Global Fund and other partners40–42.
In addition to increasing available health revenue and allocat-
ing additional resources, improved efficiencies can generate 
cost-savings, freeing up resources to cover financing gaps. 
Assessing and identifying current inefficacies and drivers of 
inefficiency can increase utilization of current funds.
Mathematical modelling suggests that the optimal mix of inter-
ventions will vary depending on the national or subnational 
setting. Reviewing efficiency of the malaria program on an annual 
basis, including an efficiency assessment as a pre-requisite for 
donor funding and linking disbursements to efficiency indic-
tors will mitigate future inefficiencies. In-country mathemati-
cal and economic modelling could support this process and thus 
efforts are being made to build national modelling capacity.
In addition to pursuing additional domestic financing and 
meeting current co-financing requirements of existing grants, 
countries should appropriately plan the transition from donor 
to domestic funding sources 3–5 years in advance of the actual 
transition. Several guidance documents and tools are available 
to support this process43.
A number of unknown factors and limitations impact the find-
ings of this report. The costs of medicines and other interventions 
have been estimated based on available data and proxies were 
used when data were unavailable. The cost of new interventions, 
such as new LLINs, and new treatments such as tafenoquine, 
were based on historical estimates of the cost of new tools when 
they were first adopted rather than actual costs. In particular, 
separating out the cost of interventions in integrated systems is 
challenging and the analysts have relied on country-level part-
ners to apportion the amounts spent on each intervention to arrive 
at disaggregated costs.
The cost estimates produced are highly dependent on the out-
put of the transmission model, which was designed with a single 
homogeneous patch for the whole of each country, using national 
level data on incidence and intervention coverage. Treating the 
whole country as a single unit in this way is likely to lead to 
over-estimates in costs of elimination. Furthermore, spatial 
heterogeneity within each country was not modelled. These 
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estimates are therefore subject to error, particularly in coun-
tries with heterogeneous transmission patterns. Elimination 
often requires targeted interventions to risk areas or populations, 
rather than ubiquitous coverage to an entire country. Without 
subnational estimates of incidence and coverage, targeted 
interventions are difficult to estimate and cost.
Due to the lack of suitable data, population movement was 
included in a rudimentary way. The transmission rate of malaria 
in each country was influenced by the malaria prevalence in 
other countries with the level of influence between countries 
reflecting a simple gravity model assumption. This assumption 
is likely to have reduced the predicted costs.
The BAU or baseline scenario refers to the range of 
interventions that were being implemented in 2015-the last avail-
able data point at the time of analysis. Substantial investments 
in the disease were made after this time particularly in the GMS 
through the Regional Artemisinin Initiative (RAI) grant from 
the Global Fund, however due to the lack of country level data 
on intervention coverage and incidence any progress made 
against the disease beyond 2015 was not built into the model. It 
is likely that the baseline estimates of disease incidence and cost 
are overestimated. Nevertheless, given the threat of drug resist-
ance already detected in the Asia Pacific, it is not surprising that 
without increased efforts to combat drug resistance the BAU 
will no longer favour a downward trend. We were unable to pre-
dict the impact that economic development and housing improve-
ments may have on malaria transmission or how the costs of 
commodities or interventions may change at the global or 
national levels. While we modelled for a declining PAR based on 
historical changes in PAR compared to changes in incidence, 
this method has limitations including a non-standardized 
definition of PAR.
While we have tried to estimate the effect that drug and insecti-
cide resistance would have on cost, it is impossible at this stage 
to predict accurately the future extent and effect of drug and 
insecticide resistance and the actual interventions that would be 
implemented to address these. In addition, the impact and cost 
of known tools in the innovation pipeline have been modelled, 
however, the impact of new tools and approaches not yet devel-
oped is unknown and will be likely to decrease costs in the long 
term given that the cost of new tools is greatest at the time of 
adoption with economies of scale and competition driving costs 
down over time. It is also difficult to predict how the costs of 
interventions may change at the regional or national levels over 
time.
Lastly, current assessments of reported malaria incidence have 
limitations. Research suggests that there may be significant 
under-reporting in the scale of global malaria incidence and mor-
tality due to the weakness of health reporting and information 
management systems as well as widespread and undocumented 
use of the private sector in many endemic countries. For example, 
the Institute for Health Metrics and Evaluation estimated a 
figure of 1.2 million malaria deaths in 2010—almost double the 
WHO’s figure of 655,00044. Similarly, a widely quoted study in 
The Lancet estimated that in India, 205,000 deaths per year could 
be attributed directly to malaria, which differed by more than ten 
times the numbers reported by the malaria program in the same 
year45.
There have been various attempts at quantifying the true burden 
of malaria and more recent publications of the World Malaria 
Reports contain data on reported cases to health facilities as 
well as estimated cases based on a number of assumptions. This 
report utilized reported cases from the World Malaria Reports 
as well as estimated cases for the Asia-Pacific countries derived 
by Mahidol-Oxford Tropical Medicine Research Unit in col-
laboration with a number of partners including the WHO12. These 
estimates were obtained by combining and triangulating data 
from a variety of data sources. Both reported and estimated 
cases are depicted in the graphs. Nevertheless, the wide variation 
in estimates of burden makes it harder to be sure of the resources 
required to eliminate the disease. Without an informed and 
complete understanding of the current cartography of malaria 
risk and prevalence, future projections of the cost of eliminating 
malaria face an overwhelming uncertainty.
The cost of malaria elimination in the Asia Pacific has been pre-
viously estimated by APLMA at USD 1 billion per year in 
the first five years of the implementation of its roadmap and just 
under USD 2 billion per year in subsequent phases, amounting 
to a total of USD 24.5 billion over 15 years. However, these costs 
were based mainly on transmission models whose exclusive 
focus was on P. falciparum malaria applying malaria transmis-
sion dynamics from Sub-Saharan African countries to predict 
90% reductions in current levels of malaria-related mortal-
ity and morbidity and not malaria elimination7. The impact of 
malaria interventions such as LLINs and IRS on P. vivax and 
other species differ vastly from what has been observed for 
P. falciparum making these previous estimates unreliable.
We believe that the benefits of elimination estimated in this paper 
are conservative. Beyond the benefits of achieving malaria elimina-
tion as explained in this report, other benefits are likely, but are 
harder to quantify as there are no reliable quantitative estimates 
on how malaria may impact these. As a by-product of national 
elimination, other positive externalities are increased tourism, a 
strengthened health system, better cognitive development, and 
improved regional health security. In addition, elimination may 
bring significant benefits to other regional public goods including 
opportunities to create stronger cross-border disease coordination. 
Because of these uncertainties, estimated costs can only pro-
vide an indicative guide or baseline to help determine financing 
needs. It is therefore important that economic estimates are con-
stantly reviewed in the light of new information, through to 2030. 
Importantly, due to the diversity of the region, further analy-
sis is required to adapt the model to individual country settings 
and develop country-level estimates based on the national con-
text. This, however, makes it even more important that funds can 
be put in place quickly to match currently expected costs.
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References
Despite limitations above, this investment case provides robust 
evidence of the benefits of continued prioritization of fund-
ing for malaria. The ROIs remain robust, comparable to those 
obtained for other high impact investments such as immunization 
programs and cardiovascular disease research46. Although the 
short-term investment needed may seem substantial, these must 
be considered in the context of other major public health, devel-
opmental projects and other national level expenditures. For 
example, the new High-Speed II railway system in the United 
Kingdom is expected to cost more than USD 70 billion, more 
than twice the amount for eliminating malaria from the Asia-
Pacific47. Similarly, in 2015, US military spending amounted to 
almost USD 600 billion48 and spending on costumes, candy and 
decorations on Halloween is expected to amount to over USD 
8 billion this year49. On the contrary, the savings from malaria 
elimination will allow the treatment of 11 million outpatients 
for 10 years or allow the construction of over 100,000 km of 
roads in Asia.
Focused advocacy at all levels is needed to reach key decision- 
makers in order to highlight the social and economic benefits 
of investing in malaria elimination and the risks of not doing 
so. In particular, emphasis on the threat of drug resistance in 
undermining success, increasing costs and posing a risk of 
regional health security is needed. Continued engagement is 
needed with governments to focus attention on increased domestic 
budgets to reach the regional goal of a malaria-free Asia-Pacific 
by 2030.
Conclusion
Global progress against malaria has been dramatic over the 
past decade. These gains, however, have been driven by substan-
tial political and financial commitments by governments and exter-
nal partners. Accelerating the trajectory of malaria elimination 
and preventing a resurgence of malaria will entail sustained com-
mitments by all stakeholders. This requires the need for accurate 
estimates of the investment required in the short, medium and 
long term as well as a robust evidence to justify the gains from 
such an investment.This analysis demonstrates that the estimated 
cost for achieving malaria elimination is outweighed by the 
significant health, economic and social benefits that will ensue 
providing an economic return of more than six times the invest-
ment. Eliminating the disease should therefore receive a spe-
cial focus for financing. Malaria is a major ongoing cost driver 
burdening national health systems and eliminating the disease 
will confer public health benefits as well as major cost savings 
to national health systems. The investments needed, while sub-
stantial in the short-term, are time-limited as costs taper off sig-
nificantly as more countries eliminate the disease. Secondly, there 
is a strong correlation between the decline in malaria burden 
and financing. Declining financing for malaria is an imminent 
threat to malaria elimination, the spread of drug resistance, and 
regional health security in the Asia-Pacific region. Lastly, malaria 
is one of the oldest diseases known to mankind: eliminating it 
will pave the way for purging other ancient infectious diseases 
of poverty. This investment case provides compelling evidence 
for the benefits of continued prioritization of funding for malaria, 
and can be used to develop an advocacy strategy for increased 
domestic and external funding for the region to reach its goal 
to be malaria-free by 2030.
Data availability
Underlying data
Data used to calibrate and validate the model were sourced 
from World Malaria Reports (2008–2016) and peer-reviewed 
literature13–23. Where there were gaps in the data, these were 
imputed based on observed changes in reported incidence.
Extended data
Zenodo: sheetalsilal/METCAP: METCAP Model. https://doi.
org/10.5281/zenodo.257547424. The following extended data are 
available:
•      Extended Cost Database.docx (Table E1. Cost estimations 
used in calculations)
Extended data are available under the terms of the Creative 
Commons Zero “No rights reserved” data waiver (CC0 1.0 
Public domain dedication).
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 Anuj Tiwari
Department of Public Health, Erasmus University Medical Center (Erasmus MC), Rotterdam, The
Netherlands
In general, the work is relevant and nicely done. Authors need to bring more clarity on the assumptions
and their basis. The modelling studies have many assumptions in general. Kindly improve the sequence
of experiments in the methodology section which is now quite unclear on how the model was
parameterized with what data. The model inputs should be in the main text in a table with clear
referencing and not in the file extension.
Below are the minor comments in detail. 
In the title, “malaria transmission elimination” is confusing because elimination of transmission is a
strange combination. Or maybe a comma between transmission and elimination may help.
 
In Cost estimates and model framework “A full description of the model framework is available
elsewhere ”. As this paper is very dependent on this model, it is recommended to present the
outline/compartments of this model framework in a figure/supplementary file in this paper. 
 
The method section is confusing because authors described the work in the previous and
current studies without clear demarcation. It is difficult to understand that what they have done in
this study. Mainly, the method section should describe the work done for this paper.
 
“A total of 80 scenarios were simulated, based on 10 different sets of packages of interventions”- in
Table 1 only 10 scenarios are mentioned. Kindly change the terminology or describe what these 80
scenarios means in the main text?
 
“Since the model did not distinguish between indigenous and imported cases, we assumed that
certain thresholds of cases are imported, which we subtracted from the model outputs”- what is the
assumed threshold? Please mention in the text.
 
“From the range of costs generated, we determined the minimum, maximum, median, mean, and
other percentiles” - of what? Economic benefit?
 
Results section:- can authors clearly describe the values or assumptions which made business as
usual having an increasing trend in the future? As described in the introduction, there is a great
success in the past in the reduction of the incidence of malaria in the region with BAU. Based on
the historic declining data, I would also expect a decline trend with BAU, but the universal coverage
will of course be expected to meet the elimination faster. 
 
The discussion should be more based on the results whereas now it is discussing out of the scope
of this paper, such as where the finances can be arranged in detail.
 
The discussion section does not contain discussion on studies or reports who worked in the same
direction or calculated elimination cost in the past.
 
There is no major explanation over the sensitivity analysis results in the discussion section. The
graph 6 and 7 needs explanation that total cost is most sensitive to what?
The conclusion section is very weak as it is generic and not based on the results or what has been
discussed. If authors can mention two points as conclusion of their results then it will make the paper
strong.
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, University of California, San Francisco, 550 16th St, 3rd Floor, Box 1224, SanRima Shretta
Francisco, USA
We thank the reviewer for his comments and suggestions for improvement.
We have added some more clarity to the assumptions and their basis where this was missing. We
have also reviewed the sequencing in the methodology section and made the steps more explicit.
We have added the table of model inputs back into the text and will discuss with the journal editors.
With respect to the minor comments:
Title: we will change to “The investment case for malaria elimination in the Asia-Pacific”
In Cost estimates and model framework: the full description of the transmission model is
available in a separate paper the same issue of this journal (they were submitted as a
package) so we do not feel that the construct of the model needs to be included here. It has
been cross-referenced.
This investment case was one part of a larger study in which a transmission model was
developed (Silal  ) and an interactive application was developed (Celhay  ). Allet al. et al.
three papers are included in this series. Nevertheless, we have reviewed the language and
made it more explicit what the methodology refers to.
Number of scenarios: A total of 80 scenarios were simulated. 10 different sets of
intervention packages were simulated with and without resistance; with and without MDA
and with and without LLIN scale-up making a total of 80.
Threshold of indigenous cases: Using Sri Lanka’s example of achieving elimination status in
2016, but reaching zero indigenous cases in October 2012, the elimination threshold was
defined as the incidence per 1000 population at risk that Sri Lanka reported to WHO in
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defined as the incidence per 1000 population at risk that Sri Lanka reported to WHO in
2013, as this is a proxy for the level of imported cases one would expect to see in a country
that has reached zero indigenous cases for the first time. This threshold was applied to the
population at risk for all 22 countries. This has been described in Silal   in this issue butet al.
details have been added in this paper as well.
From the range of costs generated, we determined the minimum, maximum, median, mean,
and other percentiles of the economic benefits. This has been added.
The BAU scenario is the range of interventions that were being implemented in 2015-the
last available data point at the time of analysis. This varies by country as each country was
implementing different interventions as outlined in their respective National Strategic Plans.
Given the threat of drug resistance already detected in the Asia Pacific, it is not surprising
that without increased efforts to combat drug resistance the BAU will no longer favor a
downward trend.
The scope of this work was to develop an investment case which also includes discussing
alternative sources of financing. Nevertheless, we have added more discussion of the
results based on the reviewer’s feedback.
A discussion on studies or reports who worked in the same direction or calculated
elimination cost in the past has been added.
A description of the sensitivity analysis has been added.
The conclusion has been revised and strengthened.
 No competing interests were disclosed.Competing Interests:
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Introductory remarks
 
Despite the significant gains made in reducing the burden of malaria in the past two decades, the disease
continues to pose a significant public health challenge, especially in sub-Saharan Africa and the
Asia-Pacific regions, requiring significant increases in investment, among other efforts, to eliminate the
disease once and for all. This “last push” has been elusive due to many factors, some of which the
authors clearly explain. Therefore, the manuscript is timely. Nonetheless, the authors are requested to
address the following specific comments to improve the article and give readers a fuller understanding of
the disease burden in the 22 countries in the region, investment needed to eliminate it and the benefits to
reap if malaria is completely eliminated by 2030.
1
2
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reap if malaria is completely eliminated by 2030.
 
Title
The title of the manuscript could be better phrased; for instance, how about “transmission and cost of
malaria elimination in the Asia-Pacific region: developing an investment case"?
 
Methods
Methods used are largely appropriate. However, the reporting of some of these methods needs further
work:
The authors are invited to clearly state the design of the study and provide a brief description of the
population being studied especially the population at risk (PAR) by country.
 
The authors are also requested to provide a table of disease (malaria) burden and gross national
income of each of the 22 countries studied in the region. This comment stems from the statement
in the “Discussion” section that suggests that since 2012, the Global Fund has been allocating
funds based on these two indicators to the countries in the region towards malaria elimination. This
proposed table will give a clearer picture of the disease burden and funds allocated over the years,
as well as the deficit/gap to fill. If possible, the amount allocated to each country by the Global fund
since 2012 should be added to the table. This proposed table can be placed in the appendix.
 
Following from the above comment and linking it to a statement in the “Discussion” section (page
12, paragraph 3, line 11–13), the authors are kindly requested to tabulate the 22 countries and their
World Bank income-defined categories, e.g. LICs, LMICs and UMICs. This can be added to the
table suggested in the previous comment.  
 
Although the authors acknowledged the limitation/discrepancies in the reported
incidence/prevalence and burden of malaria in the Asia-Pacific region by international, regional
and national bodies and other reports/literature, e.g. WHO, IHME, World Malaria Report, they can
provide a table of burden of malaria in the region using one source as suggested earlier.
 
Authors make somewhat contradictory statements in the method regarding how costs were
estimated. In one instance, they stated that the transmission model was used to estimate costs
and benefits while in another instance, they state that they “…built a cost estimation model.” In any
case, no description of the models is provided, except that authors invite readers to review other
sources; readers should not have to review other sources to get a basic understanding of these
models. It is difficult to assess the cost model and inputs. Authors are encouraged to provide brief
paragraphs explaining the key components of the cost model used.  
 
It is unclear what informed the identification/separation of activities mentioned under “cost
projections” (page 6). For instance, unit cost of vector control may consider supply chain, training.
Again, what exactly does “new treatment mean”? Is this just the cost of the new medicine or the
use of that medicine to treat cases? And for these, what specific cost items were considered?
 
What was the source of daily productivity of individuals? Again, what was the source of average
age of death due to malaria being 40 years for both males and females? Provide references for
these.
Results/discussion
The arguments made by authors relating to graduation of most countries in the region to income
levels that will lead to significant reductions in aid (page 12) could be extended, in our view.
Authors focus their argument on the (gloomy side of) reductions in development aid while
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Authors focus their argument on the (gloomy side of) reductions in development aid while
concurring that the economies of these countries could expand, raising domestic financing. While
these are true cases, authors could explore the potential of other forms of support e.g. technical
support from development agencies that do not necessarily come in the form of aid. For instance,
how can “global public goods” help in maintaining momentum for financing towards elimination?
 
The discussions of the manuscript raise important issues worth exploring. However, we believe
that those issues could be presented in a more concise form than they are currently presented. For
instance, most of the issues revolve around transition in development assistance for health in the
region as a result of economic growth, the need for increased domestic financing – not only from
government sources but also from private sources – and the opportunities provided by health
system efficiencies. We find some of these key issues scattered in the discussion, which could be
better organized.  
Minor comments
As “morbidity” could mean more than just number of cases, authors are encouraged to use “cases
averted” in place of “morbidity averted”.
 
The authors can combine paragraph 9 and 10 in page 6 under “Return on investment”.
 
The authors need to correct the following typos and also review the entire document for any
inadvertent errors.
a) Page 5, paragraph 4, line 1: Insert space between “from” and “2018”
b) Page 5, paragraph 4, line 6: Remove the second “coverage” in the sentence "LLIN coverage of
up to 80% coverage”
c) Page 6, paragraph 4, line 8: Insert space between “the” and “elimination”
d) Page 9, Paragraph 2, line 5: Insert space between “PAR’ and “in”.
 
The statement “Malaria cases and deaths have declined by more than 50% between 2010 and
2015 in the region’s 22 malaria-endemic countries”, require citation.
Concluding remarks:
The work presented in the manuscript provide important issues that could generate further discussions
around mobilizing resources for malaria elimination in the Asia-Pacific region and beyond. Addressing the
comments regarding the scientific methods applied could help improve the manuscript.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
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 Are the conclusions drawn adequately supported by the results?
Yes
 No competing interests were disclosed.Competing Interests:
We confirm that we have read this submission and believe that we have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard, however we have significant
reservations, as outlined above.
Author Response 22 Jul 2019
, University of California, San Francisco, 550 16th St, 3rd Floor, Box 1224, SanRima Shretta
Francisco, USA
We thank the reviewers for their detailed comments. Our responses are below.
 
Title
The title of the manuscript could be better phrased; for instance, how about “transmission and cost
of malaria elimination in the Asia-Pacific region: developing an investment case"?We feel that the
title should remain as is due to this work having been already cited by the associated
papers in this issue as well as other works.
1.     The authors are invited to clearly state the design of the study and provide a brief description
of the population being studied especially the population at risk (PAR) by country.
We have added the following paragraph at the beginning of the methods section:
"The study design incorporated a variety of quantitative methods: numerical and
regression techniques to develop a dynamic transmission model to predict the
epidemiological impact of various interventions used for malaria control and elimination;
and economic analysis to estimate the cost and economic impact of the interventions
nationally and regionally. The population studied was the population at risk of malaria
estimated by the WHO.  This was computed as the proportion of the population at high
and low risk of malaria (provided by the National Malaria Control Programs), applied to
the United Nations population estimates to compute the number of people at risk of
malaria. A combination of empirical, published data as well as expert opinion were used
  to develop the investment case".
2.     The authors are also requested to provide a table of disease (malaria) burden and gross
national income of each of the 22 countries studied in the region. This comment stems from the
statement in the “Discussion” section that suggests that since 2012, the Global Fund has been
allocating funds based on these two indicators to the countries in the region towards malaria
elimination. This proposed table will give a clearer picture of the disease burden and funds
allocated over the years, as well as the deficit/gap to fill. If possible, the amount allocated to each
country by the Global fund since 2012 should be added to the table. This proposed table can be
placed in the appendix.
The epidemiological data has been added as an excel file in the extended data section.
The GDP/GNI per capita already exists in the Extended Data Table 1. 
3.     Following from the above comment and linking it to a statement in the “Discussion” section
(page 12, paragraph 3, line 11–13), the authors are kindly requested to tabulate the 22 countries
and their World Bank income-defined categories, e.g. LICs, LMICs and UMICs. This can be added
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 and their World Bank income-defined categories, e.g. LICs, LMICs and UMICs. This can be added
to the table suggested in the previous comment.  
We have added a row in the existing Extended data table 1 to illustrate the World Bank
income classification. 
4.     Although the authors acknowledged the limitation/discrepancies in the reported
incidence/prevalence and burden of malaria in the Asia-Pacific region by international, regional
and national bodies and other reports/literature, e.g. WHO, IHME, World Malaria Report, they can
provide a table of burden of malaria in the region using one source as suggested earlier.
This has been addressed in 2. Above.
5.     Authors make somewhat contradictory statements in the method regarding how costs were
estimated. In one instance, they stated that the transmission model was used to estimate costs
and benefits while in another instance, they state that they “…built a cost estimation model.” In any
case, no description of the models is provided, except that authors invite readers to review other
sources; readers should not have to review other sources to get a basic understanding of these
models. It is difficult to assess the cost model and inputs. Authors are encouraged to provide brief
paragraphs explaining the key components of the cost model used.
We have modified the text to reflect this comment. The output of the transmission model
was used to estimate costs and benefits.
6.     It is unclear what informed the identification/separation of activities mentioned under “cost
projections” (page 6). For instance, unit cost of vector control may consider supply chain, training.
Again, what exactly does “new treatment mean”? Is this just the cost of the new medicine or the
use of that medicine to treat cases? And for these, what specific cost items were considered?
The costs include the cost of delivery. The text has been modified to reflect this. 
7.     What was the source of daily productivity of individuals? Again, what was the source of
average age of death due to malaria being 40 years for both males and females? Provide
references for these.
Productivity losses were calculated using the full-income approach which includes the
value of the life years and GDP per capita. We used the remaining life years at age 40 from
world life expectancy tables. This reference has been added. 
Results/discussion
1.     The arguments made by authors relating to graduation of most countries in the region to
income levels that will lead to significant reductions in aid (page 12) could be extended, in our
view. Authors focus their argument on the (gloomy side of) reductions in development aid while
concurring that the economies of these countries could expand, raising domestic financing. While
these are true cases, authors could explore the potential of other forms of support e.g. technical
support from development agencies that do not necessarily come in the form of aid. For instance,
how can “global public goods” help in maintaining momentum for financing towards elimination?
We have reviewed these sections and added some perspective to the issue of technical
assistance and global public good and their contribution to elimination. Nevertheless,
these will not fill the gaps in real financing needed to implement interventions relating to
commodity procurement or strengthening surveillance systems which tend to be human
resource heavy. 
2.     The discussions of the manuscript raise important issues worth exploring. However, we
believe that those issues could be presented in a more concise form than they are currently
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 believe that those issues could be presented in a more concise form than they are currently
presented. For instance, most of the issues revolve around transition in development assistance
for health in the region as a result of economic growth, the need for increased domestic financing –
not only from government sources but also from private sources – and the opportunities provided
by health system efficiencies. We find some of these key issues scattered in the discussion, which
could be better organized.  
We have tried to reorganize these sections. 
Minor comments
1.     As “morbidity” could mean more than just number of cases, authors are encouraged to use
“cases averted” in place of “morbidity averted”.  .Noted and this has been changed
2.     The authors can combine paragraph 9 and 10 in page 6 under “Return on investment”.  .Done
3.     The authors need to correct the following typos and also review the entire document for any
inadvertent errors. Done. 
a) Page 5, paragraph 4, line 1: Insert space between “from” and “2018”
b) Page 5, paragraph 4, line 6: Remove the second “coverage” in the sentence "LLIN coverage of
up to 80% coverage”
c) Page 6, paragraph 4, line 8: Insert space between “the” and “elimination”
d) Page 9, Paragraph 2, line 5: Insert space between “PAR’ and “in”.
4.     The statement “Malaria cases and deaths have declined by more than 50% between 2010
and 2015 in the region’s 22 malaria-endemic countries”, require citation. Done 
Concluding remarks:
The work presented in the manuscript provide important issues that could generate further
discussions around mobilizing resources for malaria elimination in the Asia-Pacific region and
beyond. Addressing the comments regarding the scientific methods applied could help improve
the manuscript.
 Thank you.
 N/A - I am the authorCompeting Interests:
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